2023 Regular Session ENROLLED
SENATE RESOLUTION NO. 101
BY SENATOR BOUDREAUX
A RESOLUTION
To urge and request the Centers for Disease Control and Prevention to include monoclonal
antibodies for respiratory syncytial virus (RSV) within the federal Vaccines for
Children program.
WHEREAS, RSV is a highly transmissible, seasonal virus which may have severe
and unpredictable outcomes for infants, including hospitalization; and
WHEREAS, nearly all children will be infected with RSV by the age of two, and
most infants requiring hospitalization were previously healthy and born at term; and
WHEREAS, RSV is the leading cause of hospitalization among infants in the United
States; and
WHEREAS, RSV is the most common cause of bronchiolitis (inflammation of the
small airways in the lungs) and pneumonia (infection of the lungs) in children younger than
one year of age in the United States; and
WHEREAS, the most recent RSV season has resulted in significant morbidity and
increased mortality; and
WHEREAS, RSV disproportionally affects infants with Medicaid coverage and
Native Americans; and
WHEREAS, the Vaccines for Children (VFC) program is a federally funded program
that provides vaccines at no cost to children who might not otherwise be vaccinated because
of an inability to pay; and
WHEREAS, VFC coverage is critical to ensure equity and ensure high uptake to
have the greatest impact on disease burden.
THEREFORE, BE IT RESOLVED that the Senate of the Legislature of Louisiana
does hereby urge and request the Centers for Disease Control and Prevention to include
monoclonal antibodies for RSV within the federal Vaccines for Children program.
PRESIDENT OF THE SENATE
Page 1 of 1